Abstract:Protein three-dimensional (3D) structure prediction is one of the most challenging issues in the field of computational biochemistry, which has overwhelmed scientists for almost half a century. A significant breakthrough in structural biology has been established by developing the artificial intelligence (AI) system AlphaFold2 (AF2). The AF2 system provides a state-of-the-art prediction of protein structures from nearly all known protein sequences with high accuracy. This study examined the reliability of AF2 models compared to the experimental structures in drug discovery, focusing on one of the most common protein drug-targeted classes known as G protein-coupled receptors (GPCRs) class A. A total of 32 representative protein targets were selected, including experimental structures of X-ray crystallographic and Cryo-EM structures and their corresponding AF2 models. The quality of AF2 models was assessed using different structure validation tools, including the pLDDT score, RMSD value, MolProbity score, percentage of Ramachandran favored, QMEAN Z-score, and QMEANDisCo Global. The molecular docking was performed using the Genetic Optimization for Ligand Docking (GOLD) software. The AF2 models' reliability in virtual drug screening was determined by their ability to predict the ligand binding poses closest to the native binding pose by assessing the Root Mean Square Deviation (RMSD) metric and docking scoring function. The quality of the docking and scoring function was evaluated using the enrichment factor (EF). Furthermore, the capability of using AF2 models in molecular docking to identify hits with key protein–ligand interactions was analyzed. The posing power results showed that the AF2 models successfully predicted ligand binding poses (RMSD < 2 Å). However, they exhibited lower screening power, with average EF values of 2.24, 2.42, and 1.82 for X-ray, Cryo-EM, and AF2 structures, respectively. Moreover, our study revealed that molecular docking using AF2 models can identify competitive inhibitors. In conclusion, this study found that AF2 models provided docking results comparable to experimental structures, particularly for certain GPCR targets, and could potentially significantly impact drug discovery.

A Benchmarking Study on Virtual Ligand Screening Against Homology Models of Human GPCRs

Reliability of Docking-Based Virtual Screening for GPCR Ligands with Homology Modeled Structures: A Case Study of the Angiotensin II Type I Receptor.

On the Value of Homology Models for Virtual Screening: Discovering hCXCR3 Antagonists by Pharmacophore-Based and Structure-Based Approaches.

Virtual screening of GPCRs: An in silico chemogenomics approach

Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You?

An Unbiased Method to Build Benchmarking Sets for Ligand-Based Virtual Screening and Its Application to GPCRs

Revolutionizing GPCR-Ligand Predictions: DeepGPCR with experimental Validation for High-Precision Drug Discovery

Revolutionizing GPCR–ligand predictions: DeepGPCR with experimental validation for high-precision drug discovery

Using molecular dynamics for the refinement of atomistic models of GPCRs by homology modeling

Discovery of GPCR ligands for probing signal transduction pathways

Structure-based pharmacophore modeling 1. Automated random pharmacophore model generation

G Protein-Coupled Receptor–Ligand Pose and Functional Class Prediction

Recent Trends and Applications of Molecular Modeling in GPCR–Ligand Recognition and Structure-Based Drug Design

Integrating Pharmacophore Into Membrane Molecular Dynamics Simulations To Improve Homology Modeling Of G Protein-Coupled Receptors With Ligand Selectivity: A(2a) Adenosine Receptor As An Example

A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening

Revisiting the Homology Modeling of G-protein Coupled Receptors: Β1-Adrenoceptor As an Example

Virtual high-throughput ligand screening.

Study on human GPCR-inhibitor interactions by proteochemometric modeling.

Homologous G Protein-Coupled Receptors Boost the Modeling and Interpretation of Bioactivities of Ligand Molecules.

Improving homology modeling from low-sequence identity templates in Rosetta: A case study in GPCRs

A Focus on Selected Class A GPCRs